- Home
- RGNX vs DGICB Comparison
RGNX vs DGICB Comparison
Compare RGNX & DGICB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RGNX | DGICB |
|---|---|---|
| Founded | 2008 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 793.5M | 889.2M |
| IPO Year | 2015 | 1995 |
Fundamental Metrics
Financial Performance| Metric | RGNX | DGICB |
|---|---|---|
| Price | $7.45 | $15.80 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $28.75 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 1.7K |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 3.34% |
| EPS Growth | ★ 18.08 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $10,393,000.00 | ★ $978,014,322.00 |
| Revenue This Year | $51.21 | $2.26 |
| Revenue Next Year | $19.08 | N/A |
| P/E Ratio | ★ N/A | $8.06 |
| Revenue Growth | ★ 126.48 | N/A |
| 52 Week Low | $5.46 | $14.87 |
| 52 Week High | $16.19 | $29.99 |
Technical Indicators
Market Signals| Indicator | RGNX | DGICB |
|---|---|---|
| Relative Strength Index (RSI) | 34.34 | 32.06 |
| Support Level | $5.67 | $15.00 |
| Resistance Level | $11.43 | $17.93 |
| Average True Range (ATR) | 0.45 | 0.96 |
| MACD | -0.06 | -0.80 |
| Stochastic Oscillator | 12.07 | 0.39 |
Price Performance
Historical ComparisonAbout RGNX REGENXBIO Inc.
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.
About DGICB Donegal Group Inc. Class B
Donegal Group Inc is an insurance holding company whose insurance subsidiaries and affiliates offer property and casualty insurance in 21 Mid-Atlantic, Midwestern, Southern, and Southwestern states. It includes three segments: Investments Function, Commercial Lines of Insurance, and Personal Lines of Insurance. The majority of revenue is from the commercial Lines segment. The commercial Lines segment consists mainly of commercial automobile, commercial multi-peril, and workers' compensation policies.